{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT02475213",
      "orgStudyIdInfo": {
        "id": "CP-MGA271-03"
      },
      "organization": {
        "fullName": "MacroGenics",
        "class": "INDUSTRY"
      },
      "briefTitle": "Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer",
      "officialTitle": "A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers"
    },
    "statusModule": {
      "statusVerifiedDate": "2025-08",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2015-07",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2021-08-18",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2021-08-18",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2015-06-16",
      "studyFirstSubmitQcDate": "2015-06-16",
      "studyFirstPostDateStruct": {
        "date": "2015-06-18",
        "type": "ESTIMATED"
      },
      "resultsFirstSubmitDate": "2023-02-14",
      "resultsFirstSubmitQcDate": "2025-08-04",
      "resultsFirstPostDateStruct": {
        "date": "2025-08-11",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2025-08-04",
      "lastUpdatePostDateStruct": {
        "date": "2025-08-11",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "MacroGenics",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Keytruda (pembrolizumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck (SCCHN), non small cell lung cancer (NSCLC), Urothelial Cancer and other B7-H3 expressing cancers. The study will also evaluate what is the highest dose of enoblituzumab that can be given safely when given with pembrolizumab. Assessments will also be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics) and to evaluate potential anti-tumor activity of MGA271 in combination with pembrolizumab. Safety and efficacy of enoblituzumab in combination with MGA012 (anti-PD-1 monoclonal antibody; also known as INCMGA00012) will also be evaluated."
    },
    "conditionsModule": {
      "conditions": [
        "Melanoma",
        "Head and Neck Cancer",
        "Non Small Cell Lung Cancer",
        "Urothelial Carcinoma"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "NON_RANDOMIZED",
        "interventionModel": "SEQUENTIAL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 146,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Cohort 1",
          "type": "EXPERIMENTAL",
          "description": "Enoblituzumab 3 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks",
          "interventionNames": [
            "Biological: Enoblituzumab Schedule 1",
            "Biological: Pembrolizumab"
          ]
        },
        {
          "label": "Cohort 2",
          "type": "EXPERIMENTAL",
          "description": "Enoblituzumab 10 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks",
          "interventionNames": [
            "Biological: Enoblituzumab Schedule 1",
            "Biological: Pembrolizumab"
          ]
        },
        {
          "label": "Cohort 3",
          "type": "EXPERIMENTAL",
          "description": "Enoblituzumab 15 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks",
          "interventionNames": [
            "Biological: Enoblituzumab Schedule 1",
            "Biological: Pembrolizumab"
          ]
        },
        {
          "label": "Cohort 4",
          "type": "EXPERIMENTAL",
          "description": "Enoblituzumab 15 mg/kg IV plus retifanlimab 375 mg IV every 3 weeks",
          "interventionNames": [
            "Biological: Enoblituzumab Schedule 2",
            "Biological: retifanlimab"
          ]
        },
        {
          "label": "Melanoma Cohort",
          "type": "EXPERIMENTAL",
          "description": "Enoblituzumab 15 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks",
          "interventionNames": [
            "Biological: Enoblituzumab Schedule 1",
            "Biological: Pembrolizumab"
          ]
        },
        {
          "label": "Urothelial Cancer Cohort",
          "type": "EXPERIMENTAL",
          "description": "Enoblituzumab 15 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks",
          "interventionNames": [
            "Biological: Enoblituzumab Schedule 1",
            "Biological: Pembrolizumab"
          ]
        },
        {
          "label": "Non-small Cell Cancer (NSCLC) Cohort",
          "type": "EXPERIMENTAL",
          "description": "Enoblituzumab 15 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks",
          "interventionNames": [
            "Biological: Enoblituzumab Schedule 1",
            "Biological: Pembrolizumab"
          ]
        },
        {
          "label": "Squamous Cell Cancer of Head and Neck (SCCHN) Cohort",
          "type": "EXPERIMENTAL",
          "description": "Enoblituzumab 15 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks",
          "interventionNames": [
            "Biological: Enoblituzumab Schedule 1",
            "Biological: Pembrolizumab"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "Enoblituzumab Schedule 1",
          "description": "enoblituzumab is administered by IV infusion once per week for up to 51 doses.",
          "armGroupLabels": [
            "Cohort 1",
            "Cohort 2",
            "Cohort 3",
            "Melanoma Cohort",
            "Non-small Cell Cancer (NSCLC) Cohort",
            "Squamous Cell Cancer of Head and Neck (SCCHN) Cohort",
            "Urothelial Cancer Cohort"
          ],
          "otherNames": [
            "MGA271"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "Pembrolizumab",
          "description": "Pembrolizumab is administered by IV infusion every 3 weeks for up to 17 doses.",
          "armGroupLabels": [
            "Cohort 1",
            "Cohort 2",
            "Cohort 3",
            "Melanoma Cohort",
            "Non-small Cell Cancer (NSCLC) Cohort",
            "Squamous Cell Cancer of Head and Neck (SCCHN) Cohort",
            "Urothelial Cancer Cohort"
          ],
          "otherNames": [
            "Keytruda"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "Enoblituzumab Schedule 2",
          "description": "Enoblituzumab is administered by IV infusion every 3 weeks for up to 17 doses",
          "armGroupLabels": [
            "Cohort 4"
          ],
          "otherNames": [
            "MGA271"
          ]
        },
        {
          "type": "BIOLOGICAL",
          "name": "retifanlimab",
          "description": "Retifanlimab is administered by IV infusion every 3 weeks for up to 17 doses",
          "armGroupLabels": [
            "Cohort 4"
          ],
          "otherNames": [
            "INCMGA00012",
            "MGA012"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Number of Participants With Dose-limiting Toxicities (DLT) After Administration of Enoblituzumab and Pembrolizumab or Retifanlimab",
          "description": "Dose-limiting toxicities are severe side effects related to study treatment that may cause dose interruptions, dose reductions, or withdrawal of treatment.",
          "timeFrame": "Study Day 1-42, for Cohorts 1-4."
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Mean Maximum Concentration of Enoblituzumab",
          "description": "The highest measured concentration of enoblizuzumab in the bloodstream.",
          "timeFrame": "Baseline, 1, 4, 24, and 72 hours after the first dose."
        },
        {
          "measure": "Mean Trough Concentration of Enoblituzumab",
          "description": "Trough concentration is the concentration measured before the a subsequent dose of enoblituzumab.\n\nMGA271 is characterized by a biphasic concentration-time profile and PPK was used to estimate PK parameters at each dose level",
          "timeFrame": "At baseline, and Day 7."
        },
        {
          "measure": "Mean Area Under the Concentration Time Curve (AUC) From Time 0 to Day 7 of Enoblituzumab",
          "description": "AUC is the total body exposure to enoblituzumab MGA271 is characterized by a biphasic concentration-time profile and PPK was used to estimate PK parameters at each dose level",
          "timeFrame": "At baseline, 1, 4, 24, 72 hours, and Day 7."
        },
        {
          "measure": "Mean Clearance of Enoblituzumab",
          "description": "Drug clearance is the amount of drug removed from the bloodstream by the body per unit of time.",
          "timeFrame": "At baseline, 1, 4, 24, 72 hours, and Day 7."
        },
        {
          "measure": "Mean Volume of Distribution at Steady State of Enoblituzumab in Combination With Pembrolizumab or Retifanlimab",
          "description": "The volume of distribution is related to how much drug is distributed to body tissues, or remains in the bloodstream",
          "timeFrame": "At baseline, 1, 4, 24, and 72 and Day 7."
        },
        {
          "measure": "Mean Terminal Half-life of Enoblituzumab in Combination With Pembrolizumab or Retifanlimab",
          "description": "Terminal half-life is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium MGA271 is characterized by a biphasic concentration-time profile and PPK was used to estimate PK parameters at each dose level",
          "timeFrame": "At baseline, 1, 4, 24, and 72 and Day 7."
        },
        {
          "measure": "Number of Participants That Develop Enoblituzumab Anti-drug Antibodies (ADA)",
          "timeFrame": "Every 3 weeks throughout the study, average duration 13 months."
        },
        {
          "measure": "Number of Participants That Develop Retifanlimab ADA",
          "timeFrame": "Every 3 weeks throughout the study, average duration 13 months."
        },
        {
          "measure": "Objective Response Rate",
          "description": "The number of participants with a complete response (CR) or partial response (PR) to enoblituzumab in combination with pembrolizumab or retifanlimab RECIST 1.1 criteria.",
          "timeFrame": "Six weeks after the first dose, then every 9 weeks throughout study until discontinuation, average 13 months"
        },
        {
          "measure": "ORR Using Immune-related (ir) RECIST Criteria",
          "description": "The number of participants with a complete response (CR) or partial response (PR) to enoblituzumab in combination with pembrolizumab or retifanlimab using irRECIST 1.1 criteria.",
          "timeFrame": "Six weeks after the first dose, then every 9 weeks throughout study until discontinuation, average 13 months"
        },
        {
          "measure": "Best Overall Response (RECIST 1.1)",
          "description": "The participants best response to treatment during their study participation. Responses are categorized as CR, PR, stable disease (SD), progressive disease (PD) or not evaluated (NE)",
          "timeFrame": "Evaluated at 6 weeks then every 9 weeks throughout the study until discontinuation, average 13 months."
        },
        {
          "measure": "Best Overall Response (irRECIST 1.1)",
          "description": "The participants best response to treatment during their study participation. Responses are categorized as CR, PR, stable disease (SD), progressive disease (PD) or not evaluated (NE)",
          "timeFrame": "Evaluated at 6 weeks then every 9 weeks throughout the study until discontinuation, average 13 months."
        },
        {
          "measure": "Minimum and Maximum Duration of Response (DoR) Per irRECIST 1.1",
          "description": "The duration of response displays the minimum and maximum range in months from the first documented CR or PR until disease progression or death, whichever is first.",
          "timeFrame": "Evaluated at 6 weeks then every 9 weeks throughout the study until discontinuation, average13 months."
        },
        {
          "measure": "Minimum and Maximum DoR Per RECIST 1.1",
          "description": "The duration of response displays the minimum and maximum range in months from the first documented CR or PR until disease progression or death, whichever is first.",
          "timeFrame": "Evaluated at 6 weeks then every 9 weeks throughout the study until discontinuation, average 13 months."
        },
        {
          "measure": "Median Progression-free Survival (PFS) Using RECIST 1.1",
          "description": "The time from the first infusion of pembrolizumab or retifanlimab until documented disease progression or death from any cause.",
          "timeFrame": "Evaluated at 6 weeks then every 9 weeks throughout the study until discontinuation, average 13 months."
        },
        {
          "measure": "Median PFS Using irRECIST 1.1 Criteria",
          "description": "The time from the first infusion of pembrolizumab or retifanlimab until documented disease progression or death from any cause.",
          "timeFrame": "Evaluated at 6 weeks then every 9 weeks throughout the study until discontinuation, average 13 months."
        },
        {
          "measure": "Median Overall Survival",
          "description": "The time from the first infusion of pembrolizumab or retifanlimab until death from any cause.",
          "timeFrame": "Evaluated at 6 weeks then every 9 weeks throughout the study until discontinuation, average 13 months."
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* To enroll on cohorts 1-4, participants must have a histologically-proven, previously treated, unresectable, locally advanced or metastatic mesothelioma, urothelial cancer, thyroid cancer, pancreatic cancer, ovarian cancer, colon cancer, prostate cancer, soft tissue sarcoma, triple negative breast cancer, renal clear cell cancer, melanoma, squamous cell cancer of the head and neck, or non-small cell lung cancer.\n* Participants on the melanoma cohort must have progressed on or after at least one anti-PD-L1 or anti- PD-1 containing therapy.\n* Participants on the SCCHN cohort must have progressed on or after platinum-based systemic therapy\n* Participants on the NSCLC cohort must have progressed on or after first line systemic therapy\n* Participants on the urothelial cancer cohort must have received at least one platinum-containing regimen and have progressed on or after an anti-PD-L1 or anti-PD-1 containing therapy\n* Measurable disease per RECIST 1.1 criteria\n* Easter Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Acceptable laboratory parameters and adequate organ reserve.\n\nExclusion Criteria:\n\n* Patients with a history of symptomatic central nervous system metastases, unless treated and asymptomatic\n* Patients with history of autoimmune disease with certain exceptions such as vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring systemic therapy within the past 2 years, patients with history of Grave's disease that are now euthyroid clinically and by lab testing\n* History of allogeneic bone marrow, stem cell, or solid organ transplant\n* Treatment with systemic cancer therapy or investigational therapy within 4 weeks of first study drug administration; radiation within 2 weeks; corticosteroids (greater than or equal to 10 mg prednisone or equivalent per day) or other immune suppressive drugs within 2 weeks of first study drug administration\n* Trauma or major surgery within 4 weeks of first study drug administration\n* History of clinically-significant cardiovascular disease; gastrointestinal perforation; gastrointestinal bleeding, acute pancreatitis or diverticulitis within 4 weeks of first study drug administration\n* Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days of first study drug administration\n* Known history of hepatitis B or C infection or known positive test for hepatitis B surface antigen or core antigen, or hepatitis C polymerase chain reaction (PCR)\n* Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome\n* Known hypersensitivity to recombinant proteins, polysorbate 80, or any excipient contained in the drug or vehicle formulation for MGA271 or pembrolizumab.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Ashley Ward, MD",
          "affiliation": "MacroGenics",
          "role": "STUDY_DIRECTOR"
        }
      ],
      "locations": [
        {
          "facility": "Mayo Clinic - AZ",
          "city": "Scottsdale",
          "state": "Arizona",
          "zip": "85259",
          "country": "United States",
          "geoPoint": {
            "lat": 33.50921,
            "lon": -111.89903
          }
        },
        {
          "facility": "Christiana Care Health Services, Inc.",
          "city": "Newark",
          "state": "Delaware",
          "zip": "19713",
          "country": "United States",
          "geoPoint": {
            "lat": 39.68372,
            "lon": -75.74966
          }
        },
        {
          "facility": "Mayo Clinic - FL",
          "city": "Jacksonville",
          "state": "Florida",
          "zip": "32224",
          "country": "United States",
          "geoPoint": {
            "lat": 30.33218,
            "lon": -81.65565
          }
        },
        {
          "facility": "Moffitt Cancer Center",
          "city": "Tampa",
          "state": "Florida",
          "zip": "33612",
          "country": "United States",
          "geoPoint": {
            "lat": 27.94752,
            "lon": -82.45843
          }
        },
        {
          "facility": "Norton Cancer Institute Research Program",
          "city": "Louisville",
          "state": "Kentucky",
          "zip": "40202",
          "country": "United States",
          "geoPoint": {
            "lat": 38.25424,
            "lon": -85.75941
          }
        },
        {
          "facility": "University of Maryland Greenbaum Cancer Center",
          "city": "Baltimore",
          "state": "Maryland",
          "zip": "21201",
          "country": "United States",
          "geoPoint": {
            "lat": 39.29038,
            "lon": -76.61219
          }
        },
        {
          "facility": "Dana-Farber Cancer Institute",
          "city": "Boston",
          "state": "Massachusetts",
          "zip": "02215",
          "country": "United States",
          "geoPoint": {
            "lat": 42.35843,
            "lon": -71.05977
          }
        },
        {
          "facility": "South Texas Accelerated Research Therapeutics, LLC - Midwest",
          "city": "Grand Rapids",
          "state": "Michigan",
          "zip": "49503",
          "country": "United States",
          "geoPoint": {
            "lat": 42.96336,
            "lon": -85.66809
          }
        },
        {
          "facility": "Mayo Clinic - MN",
          "city": "Rochester",
          "state": "Minnesota",
          "zip": "55905",
          "country": "United States",
          "geoPoint": {
            "lat": 44.02163,
            "lon": -92.4699
          }
        },
        {
          "facility": "Nebraska Cancer Specialists",
          "city": "Omaha",
          "state": "Nebraska",
          "zip": "68130",
          "country": "United States",
          "geoPoint": {
            "lat": 41.25626,
            "lon": -95.94043
          }
        },
        {
          "facility": "Comprehensive Cancer Centers of Nevada",
          "city": "Las Vegas",
          "state": "Nevada",
          "zip": "89169",
          "country": "United States",
          "geoPoint": {
            "lat": 36.17497,
            "lon": -115.13722
          }
        },
        {
          "facility": "Roswell Park Cancer Institute",
          "city": "Buffalo",
          "state": "New York",
          "zip": "14263",
          "country": "United States",
          "geoPoint": {
            "lat": 42.88645,
            "lon": -78.87837
          }
        },
        {
          "facility": "Columbia University Medical Center",
          "city": "New York",
          "state": "New York",
          "zip": "10032",
          "country": "United States",
          "geoPoint": {
            "lat": 40.71427,
            "lon": -74.00597
          }
        },
        {
          "facility": "Gabrail Cancer Institute",
          "city": "Canton",
          "state": "Ohio",
          "zip": "44718",
          "country": "United States",
          "geoPoint": {
            "lat": 40.79895,
            "lon": -81.37845
          }
        },
        {
          "facility": "Hospital of the University of Pennsylvania/Abramson Cancer Center",
          "city": "Philadelphia",
          "state": "Pennsylvania",
          "zip": "19104",
          "country": "United States",
          "geoPoint": {
            "lat": 39.95238,
            "lon": -75.16362
          }
        },
        {
          "facility": "University of Pittsburg",
          "city": "Pittsburgh",
          "state": "Pennsylvania",
          "zip": "15232",
          "country": "United States",
          "geoPoint": {
            "lat": 40.44062,
            "lon": -79.99589
          }
        },
        {
          "facility": "Rhode Island Hospital",
          "city": "Providence",
          "state": "Rhode Island",
          "zip": "02903",
          "country": "United States",
          "geoPoint": {
            "lat": 41.82399,
            "lon": -71.41283
          }
        },
        {
          "facility": "Greenville Health System",
          "city": "Greenville",
          "state": "South Carolina",
          "zip": "29605",
          "country": "United States",
          "geoPoint": {
            "lat": 34.85262,
            "lon": -82.39401
          }
        },
        {
          "facility": "Mary Crowley Cancer Research Center",
          "city": "Dallas",
          "state": "Texas",
          "zip": "75230",
          "country": "United States",
          "geoPoint": {
            "lat": 32.78306,
            "lon": -96.80667
          }
        },
        {
          "facility": "South Texas Accelerated Research Therapeutics, LLC",
          "city": "San Antonio",
          "state": "Texas",
          "zip": "78229",
          "country": "United States",
          "geoPoint": {
            "lat": 29.42412,
            "lon": -98.49363
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "35414591",
          "type": "DERIVED",
          "citation": "Aggarwal C, Prawira A, Antonia S, Rahma O, Tolcher A, Cohen RB, Lou Y, Hauke R, Vogelzang N, P Zandberg D, Kalebasty AR, Atkinson V, Adjei AA, Seetharam M, Birnbaum A, Weickhardt A, Ganju V, Joshua AM, Cavallo R, Peng L, Zhang X, Kaul S, Baughman J, Bonvini E, Moore PA, Goldberg SM, Arnaldez FI, Ferris RL, Lakhani NJ. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. J Immunother Cancer. 2022 Apr;10(4):e004424. doi: 10.1136/jitc-2021-004424."
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "resultsSection": {
    "participantFlowModule": {
      "groups": [
        {
          "id": "FG000",
          "title": "Cohort 1",
          "description": "enoblituzumab 3 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
        },
        {
          "id": "FG001",
          "title": "Cohort 2",
          "description": "enoblituzumab 10 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
        },
        {
          "id": "FG002",
          "title": "Cohort 3",
          "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
        },
        {
          "id": "FG003",
          "title": "Melanoma Cohort",
          "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
        },
        {
          "id": "FG004",
          "title": "Urothelial Cancer Cohort",
          "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
        },
        {
          "id": "FG005",
          "title": "NSCLC Cohort",
          "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
        },
        {
          "id": "FG006",
          "title": "SCCHN Cohort",
          "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
        },
        {
          "id": "FG007",
          "title": "Cohort 4",
          "description": "enoblituzumab 15 mg/kg IV and retifanlimab 375 mg IV every 3 weeks for up to 17 doses."
        }
      ],
      "periods": [
        {
          "title": "Overall Study",
          "milestones": [
            {
              "type": "STARTED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "6"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "3"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "3"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "17"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "21"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "40"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "44"
                },
                {
                  "groupId": "FG007",
                  "numSubjects": "12"
                }
              ]
            },
            {
              "type": "Safety Population",
              "comment": "Includes all participants receiving at least 1 dose of enoblituzumab.",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "6"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "3"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "3"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "17"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "21"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "40"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "43"
                },
                {
                  "groupId": "FG007",
                  "numSubjects": "12"
                }
              ]
            },
            {
              "type": "PK Population",
              "comment": "Includes all participants where PK samples could be analyzed.",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "6"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "3"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "3"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "17"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "21"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "39"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "42"
                },
                {
                  "groupId": "FG007",
                  "numSubjects": "12"
                }
              ]
            },
            {
              "type": "Response Evaluable Population",
              "comment": "Includes all participants with pre-dose tumor assessment and at least 1 post-dose tumor assessment.",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "6"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "3"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "3"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "15"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "17"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "34"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "35"
                },
                {
                  "groupId": "FG007",
                  "numSubjects": "11"
                }
              ]
            },
            {
              "type": "COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "3"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG007",
                  "numSubjects": "0"
                }
              ]
            },
            {
              "type": "NOT COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "6"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "3"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "3"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "16"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "20"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "37"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "43"
                },
                {
                  "groupId": "FG007",
                  "numSubjects": "12"
                }
              ]
            }
          ],
          "dropWithdraws": [
            {
              "type": "Adverse Event",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "2"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "4"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "6"
                },
                {
                  "groupId": "FG007",
                  "numSubjects": "2"
                }
              ]
            },
            {
              "type": "Physician Decision",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "4"
                },
                {
                  "groupId": "FG007",
                  "numSubjects": "0"
                }
              ]
            },
            {
              "type": "Progressive Disease",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "3"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "2"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "2"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "13"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "15"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "25"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "30"
                },
                {
                  "groupId": "FG007",
                  "numSubjects": "10"
                }
              ]
            },
            {
              "type": "Death",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "4"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG007",
                  "numSubjects": "0"
                }
              ]
            },
            {
              "type": "Protocol Violation",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG007",
                  "numSubjects": "0"
                }
              ]
            },
            {
              "type": "Withdrawal by Subject",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "2"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "2"
                },
                {
                  "groupId": "FG007",
                  "numSubjects": "0"
                }
              ]
            },
            {
              "type": "Other",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG001",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG002",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG003",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG004",
                  "numSubjects": "3"
                },
                {
                  "groupId": "FG005",
                  "numSubjects": "1"
                },
                {
                  "groupId": "FG006",
                  "numSubjects": "0"
                },
                {
                  "groupId": "FG007",
                  "numSubjects": "0"
                }
              ]
            }
          ]
        }
      ]
    },
    "baselineCharacteristicsModule": {
      "groups": [
        {
          "id": "BG000",
          "title": "Cohort 1",
          "description": "enoblituzumab 3 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
        },
        {
          "id": "BG001",
          "title": "Cohort 2",
          "description": "enoblituzumab 10 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
        },
        {
          "id": "BG002",
          "title": "Cohort 3",
          "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
        },
        {
          "id": "BG003",
          "title": "Melanoma Expansion",
          "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
        },
        {
          "id": "BG004",
          "title": "Urothelial Cancer Expansion",
          "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
        },
        {
          "id": "BG005",
          "title": "NSCLC Expansion",
          "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
        },
        {
          "id": "BG006",
          "title": "SCCHN Expansion",
          "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
        },
        {
          "id": "BG007",
          "title": "Cohort 4",
          "description": "enoblituzumab 15 mg/kg IV and retifanlimab 375 mg IV every three weeks for up to 17 doses.."
        },
        {
          "id": "BG008",
          "title": "Total",
          "description": "Total of all reporting groups"
        }
      ],
      "denoms": [
        {
          "units": "Participants",
          "counts": [
            {
              "groupId": "BG000",
              "value": "6"
            },
            {
              "groupId": "BG001",
              "value": "3"
            },
            {
              "groupId": "BG002",
              "value": "3"
            },
            {
              "groupId": "BG003",
              "value": "17"
            },
            {
              "groupId": "BG004",
              "value": "21"
            },
            {
              "groupId": "BG005",
              "value": "40"
            },
            {
              "groupId": "BG006",
              "value": "43"
            },
            {
              "groupId": "BG007",
              "value": "12"
            },
            {
              "groupId": "BG008",
              "value": "145"
            }
          ]
        }
      ],
      "measures": [
        {
          "title": "Age, Continuous",
          "paramType": "MEAN",
          "dispersionType": "STANDARD_DEVIATION",
          "unitOfMeasure": "years",
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "64.0",
                      "spread": "7.85"
                    },
                    {
                      "groupId": "BG001",
                      "value": "41.7",
                      "spread": "25.38"
                    },
                    {
                      "groupId": "BG002",
                      "value": "74.7",
                      "spread": "14.64"
                    },
                    {
                      "groupId": "BG003",
                      "value": "62.9",
                      "spread": "14.92"
                    },
                    {
                      "groupId": "BG004",
                      "value": "67.2",
                      "spread": "9.24"
                    },
                    {
                      "groupId": "BG005",
                      "value": "64.8",
                      "spread": "8.20"
                    },
                    {
                      "groupId": "BG006",
                      "value": "62.7",
                      "spread": "9.63"
                    },
                    {
                      "groupId": "BG007",
                      "value": "62.4",
                      "spread": "12.09"
                    },
                    {
                      "groupId": "BG008",
                      "value": "63.8",
                      "spread": "11.06"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Sex: Female, Male",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "Female",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "3"
                    },
                    {
                      "groupId": "BG001",
                      "value": "2"
                    },
                    {
                      "groupId": "BG002",
                      "value": "1"
                    },
                    {
                      "groupId": "BG003",
                      "value": "6"
                    },
                    {
                      "groupId": "BG004",
                      "value": "6"
                    },
                    {
                      "groupId": "BG005",
                      "value": "18"
                    },
                    {
                      "groupId": "BG006",
                      "value": "5"
                    },
                    {
                      "groupId": "BG007",
                      "value": "6"
                    },
                    {
                      "groupId": "BG008",
                      "value": "47"
                    }
                  ]
                },
                {
                  "title": "Male",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "3"
                    },
                    {
                      "groupId": "BG001",
                      "value": "1"
                    },
                    {
                      "groupId": "BG002",
                      "value": "2"
                    },
                    {
                      "groupId": "BG003",
                      "value": "11"
                    },
                    {
                      "groupId": "BG004",
                      "value": "15"
                    },
                    {
                      "groupId": "BG005",
                      "value": "22"
                    },
                    {
                      "groupId": "BG006",
                      "value": "38"
                    },
                    {
                      "groupId": "BG007",
                      "value": "6"
                    },
                    {
                      "groupId": "BG008",
                      "value": "98"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Ethnicity (NIH/OMB)",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "Hispanic or Latino",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "1"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "0"
                    },
                    {
                      "groupId": "BG004",
                      "value": "0"
                    },
                    {
                      "groupId": "BG005",
                      "value": "2"
                    },
                    {
                      "groupId": "BG006",
                      "value": "2"
                    },
                    {
                      "groupId": "BG007",
                      "value": "1"
                    },
                    {
                      "groupId": "BG008",
                      "value": "6"
                    }
                  ]
                },
                {
                  "title": "Not Hispanic or Latino",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "5"
                    },
                    {
                      "groupId": "BG001",
                      "value": "3"
                    },
                    {
                      "groupId": "BG002",
                      "value": "3"
                    },
                    {
                      "groupId": "BG003",
                      "value": "16"
                    },
                    {
                      "groupId": "BG004",
                      "value": "21"
                    },
                    {
                      "groupId": "BG005",
                      "value": "37"
                    },
                    {
                      "groupId": "BG006",
                      "value": "41"
                    },
                    {
                      "groupId": "BG007",
                      "value": "10"
                    },
                    {
                      "groupId": "BG008",
                      "value": "136"
                    }
                  ]
                },
                {
                  "title": "Unknown or Not Reported",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "1"
                    },
                    {
                      "groupId": "BG004",
                      "value": "0"
                    },
                    {
                      "groupId": "BG005",
                      "value": "1"
                    },
                    {
                      "groupId": "BG006",
                      "value": "0"
                    },
                    {
                      "groupId": "BG007",
                      "value": "1"
                    },
                    {
                      "groupId": "BG008",
                      "value": "3"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Race (NIH/OMB)",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "American Indian or Alaska Native",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "0"
                    },
                    {
                      "groupId": "BG004",
                      "value": "0"
                    },
                    {
                      "groupId": "BG005",
                      "value": "1"
                    },
                    {
                      "groupId": "BG006",
                      "value": "0"
                    },
                    {
                      "groupId": "BG007",
                      "value": "0"
                    },
                    {
                      "groupId": "BG008",
                      "value": "1"
                    }
                  ]
                },
                {
                  "title": "Asian",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "0"
                    },
                    {
                      "groupId": "BG004",
                      "value": "0"
                    },
                    {
                      "groupId": "BG005",
                      "value": "0"
                    },
                    {
                      "groupId": "BG006",
                      "value": "1"
                    },
                    {
                      "groupId": "BG007",
                      "value": "0"
                    },
                    {
                      "groupId": "BG008",
                      "value": "1"
                    }
                  ]
                },
                {
                  "title": "Native Hawaiian or Other Pacific Islander",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "0"
                    },
                    {
                      "groupId": "BG004",
                      "value": "0"
                    },
                    {
                      "groupId": "BG005",
                      "value": "0"
                    },
                    {
                      "groupId": "BG006",
                      "value": "0"
                    },
                    {
                      "groupId": "BG007",
                      "value": "0"
                    },
                    {
                      "groupId": "BG008",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Black or African American",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "0"
                    },
                    {
                      "groupId": "BG004",
                      "value": "1"
                    },
                    {
                      "groupId": "BG005",
                      "value": "2"
                    },
                    {
                      "groupId": "BG006",
                      "value": "6"
                    },
                    {
                      "groupId": "BG007",
                      "value": "3"
                    },
                    {
                      "groupId": "BG008",
                      "value": "12"
                    }
                  ]
                },
                {
                  "title": "White",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "6"
                    },
                    {
                      "groupId": "BG001",
                      "value": "3"
                    },
                    {
                      "groupId": "BG002",
                      "value": "3"
                    },
                    {
                      "groupId": "BG003",
                      "value": "17"
                    },
                    {
                      "groupId": "BG004",
                      "value": "19"
                    },
                    {
                      "groupId": "BG005",
                      "value": "36"
                    },
                    {
                      "groupId": "BG006",
                      "value": "34"
                    },
                    {
                      "groupId": "BG007",
                      "value": "8"
                    },
                    {
                      "groupId": "BG008",
                      "value": "126"
                    }
                  ]
                },
                {
                  "title": "More than one race",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "0"
                    },
                    {
                      "groupId": "BG004",
                      "value": "0"
                    },
                    {
                      "groupId": "BG005",
                      "value": "0"
                    },
                    {
                      "groupId": "BG006",
                      "value": "0"
                    },
                    {
                      "groupId": "BG007",
                      "value": "0"
                    },
                    {
                      "groupId": "BG008",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Unknown or Not Reported",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "0"
                    },
                    {
                      "groupId": "BG004",
                      "value": "1"
                    },
                    {
                      "groupId": "BG005",
                      "value": "1"
                    },
                    {
                      "groupId": "BG006",
                      "value": "2"
                    },
                    {
                      "groupId": "BG007",
                      "value": "1"
                    },
                    {
                      "groupId": "BG008",
                      "value": "5"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Region of Enrollment",
          "paramType": "NUMBER",
          "unitOfMeasure": "participants",
          "classes": [
            {
              "title": "United States",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "6"
                    },
                    {
                      "groupId": "BG001",
                      "value": "3"
                    },
                    {
                      "groupId": "BG002",
                      "value": "3"
                    },
                    {
                      "groupId": "BG003",
                      "value": "14"
                    },
                    {
                      "groupId": "BG004",
                      "value": "19"
                    },
                    {
                      "groupId": "BG005",
                      "value": "37"
                    },
                    {
                      "groupId": "BG006",
                      "value": "36"
                    },
                    {
                      "groupId": "BG007",
                      "value": "9"
                    },
                    {
                      "groupId": "BG008",
                      "value": "126"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Australia",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "3"
                    },
                    {
                      "groupId": "BG004",
                      "value": "2"
                    },
                    {
                      "groupId": "BG005",
                      "value": "2"
                    },
                    {
                      "groupId": "BG006",
                      "value": "7"
                    },
                    {
                      "groupId": "BG007",
                      "value": "3"
                    },
                    {
                      "groupId": "BG008",
                      "value": "17"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Canada",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "0"
                    },
                    {
                      "groupId": "BG004",
                      "value": "0"
                    },
                    {
                      "groupId": "BG005",
                      "value": "1"
                    },
                    {
                      "groupId": "BG006",
                      "value": "0"
                    },
                    {
                      "groupId": "BG007",
                      "value": "0"
                    },
                    {
                      "groupId": "BG008",
                      "value": "1"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "ECOG Performance Status",
          "description": "The ECOG Performance Status describes patients level of functioning in terms of their ability to care for themselves, daily activity, and physical ability (walking, working, etc.). Lower scores indicate a more self-sufficient level of functioning.",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "ECOG 0",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "2"
                    },
                    {
                      "groupId": "BG001",
                      "value": "1"
                    },
                    {
                      "groupId": "BG002",
                      "value": "1"
                    },
                    {
                      "groupId": "BG003",
                      "value": "5"
                    },
                    {
                      "groupId": "BG004",
                      "value": "5"
                    },
                    {
                      "groupId": "BG005",
                      "value": "8"
                    },
                    {
                      "groupId": "BG006",
                      "value": "13"
                    },
                    {
                      "groupId": "BG007",
                      "value": "4"
                    },
                    {
                      "groupId": "BG008",
                      "value": "39"
                    }
                  ]
                },
                {
                  "title": "ECOG 1",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "4"
                    },
                    {
                      "groupId": "BG001",
                      "value": "2"
                    },
                    {
                      "groupId": "BG002",
                      "value": "2"
                    },
                    {
                      "groupId": "BG003",
                      "value": "10"
                    },
                    {
                      "groupId": "BG004",
                      "value": "16"
                    },
                    {
                      "groupId": "BG005",
                      "value": "32"
                    },
                    {
                      "groupId": "BG006",
                      "value": "29"
                    },
                    {
                      "groupId": "BG007",
                      "value": "8"
                    },
                    {
                      "groupId": "BG008",
                      "value": "103"
                    }
                  ]
                },
                {
                  "title": "Not reported",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "2"
                    },
                    {
                      "groupId": "BG004",
                      "value": "0"
                    },
                    {
                      "groupId": "BG005",
                      "value": "0"
                    },
                    {
                      "groupId": "BG006",
                      "value": "1"
                    },
                    {
                      "groupId": "BG007",
                      "value": "0"
                    },
                    {
                      "groupId": "BG008",
                      "value": "3"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Height",
          "paramType": "MEAN",
          "dispersionType": "STANDARD_DEVIATION",
          "unitOfMeasure": "Centimeters",
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "164.34",
                      "spread": "10.12"
                    },
                    {
                      "groupId": "BG001",
                      "value": "168.5",
                      "spread": "6.44"
                    },
                    {
                      "groupId": "BG002",
                      "value": "170.4",
                      "spread": "7.66"
                    },
                    {
                      "groupId": "BG003",
                      "value": "173.0",
                      "spread": "10.41"
                    },
                    {
                      "groupId": "BG004",
                      "value": "173.4",
                      "spread": "9.18"
                    },
                    {
                      "groupId": "BG005",
                      "value": "169.4",
                      "spread": "9.62"
                    },
                    {
                      "groupId": "BG006",
                      "value": "175.3",
                      "spread": "6.31"
                    },
                    {
                      "groupId": "BG007",
                      "value": "167.0",
                      "spread": "15.93"
                    },
                    {
                      "groupId": "BG008",
                      "value": "171.8",
                      "spread": "9.72"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Weight",
          "paramType": "MEAN",
          "dispersionType": "STANDARD_DEVIATION",
          "unitOfMeasure": "Kilograms",
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "73.2",
                      "spread": "8.67"
                    },
                    {
                      "groupId": "BG001",
                      "value": "63.1",
                      "spread": "16.14"
                    },
                    {
                      "groupId": "BG002",
                      "value": "79.0",
                      "spread": "4.55"
                    },
                    {
                      "groupId": "BG003",
                      "value": "81.5",
                      "spread": "24.82"
                    },
                    {
                      "groupId": "BG004",
                      "value": "82.7",
                      "spread": "17.63"
                    },
                    {
                      "groupId": "BG005",
                      "value": "74.4",
                      "spread": "17.15"
                    },
                    {
                      "groupId": "BG006",
                      "value": "75.6",
                      "spread": "13.60"
                    },
                    {
                      "groupId": "BG007",
                      "value": "91.1",
                      "spread": "35.44"
                    },
                    {
                      "groupId": "BG008",
                      "value": "78.0",
                      "spread": "19.43"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "B7H3 immunohistochemistry status",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "Positive",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "4"
                    },
                    {
                      "groupId": "BG001",
                      "value": "1"
                    },
                    {
                      "groupId": "BG002",
                      "value": "2"
                    },
                    {
                      "groupId": "BG003",
                      "value": "16"
                    },
                    {
                      "groupId": "BG004",
                      "value": "15"
                    },
                    {
                      "groupId": "BG005",
                      "value": "32"
                    },
                    {
                      "groupId": "BG006",
                      "value": "37"
                    },
                    {
                      "groupId": "BG007",
                      "value": "9"
                    },
                    {
                      "groupId": "BG008",
                      "value": "116"
                    }
                  ]
                },
                {
                  "title": "Negative",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    },
                    {
                      "groupId": "BG001",
                      "value": "0"
                    },
                    {
                      "groupId": "BG002",
                      "value": "0"
                    },
                    {
                      "groupId": "BG003",
                      "value": "0"
                    },
                    {
                      "groupId": "BG004",
                      "value": "4"
                    },
                    {
                      "groupId": "BG005",
                      "value": "3"
                    },
                    {
                      "groupId": "BG006",
                      "value": "5"
                    },
                    {
                      "groupId": "BG007",
                      "value": "3"
                    },
                    {
                      "groupId": "BG008",
                      "value": "15"
                    }
                  ]
                },
                {
                  "title": "Unknown",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "2"
                    },
                    {
                      "groupId": "BG001",
                      "value": "2"
                    },
                    {
                      "groupId": "BG002",
                      "value": "1"
                    },
                    {
                      "groupId": "BG003",
                      "value": "1"
                    },
                    {
                      "groupId": "BG004",
                      "value": "2"
                    },
                    {
                      "groupId": "BG005",
                      "value": "5"
                    },
                    {
                      "groupId": "BG006",
                      "value": "1"
                    },
                    {
                      "groupId": "BG007",
                      "value": "0"
                    },
                    {
                      "groupId": "BG008",
                      "value": "14"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "outcomeMeasuresModule": {
      "outcomeMeasures": [
        {
          "type": "PRIMARY",
          "title": "Number of Participants With Dose-limiting Toxicities (DLT) After Administration of Enoblituzumab and Pembrolizumab or Retifanlimab",
          "description": "Dose-limiting toxicities are severe side effects related to study treatment that may cause dose interruptions, dose reductions, or withdrawal of treatment.",
          "populationDescription": "Participants in Cohorts 1-4 are evaluable for DLT during the first 42 days of treatment.",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "Study Day 1-42, for Cohorts 1-4.",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort 1",
              "description": "enoblituzumab 3 mg/kg IV weekly for up to 51 doses plus pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG001",
              "title": "Cohort 2",
              "description": "enoblituzumab 10 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG002",
              "title": "Cohort 3",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG003",
              "title": "Cohort 4",
              "description": "enoblituzumab 15 mg/kg IV and retifanlimab 375 mg IV every three weeks for up to 17 doses."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "6"
                },
                {
                  "groupId": "OG001",
                  "value": "3"
                },
                {
                  "groupId": "OG002",
                  "value": "3"
                },
                {
                  "groupId": "OG003",
                  "value": "12"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0"
                    },
                    {
                      "groupId": "OG002",
                      "value": "0"
                    },
                    {
                      "groupId": "OG003",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Mean Maximum Concentration of Enoblituzumab",
          "description": "The highest measured concentration of enoblizuzumab in the bloodstream.",
          "populationDescription": "All participants who received at least one dose of study treatment, date and time of dose administration and relative PK sample collection are known and have sufficient concentration data to derive the PK parameter. PK parameters are analyzed by the dose received. Participants in Cohort 3 and the Expansion Cohorts were combined since all participants were dosed at 15 mg/kg.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "mcg/mL",
          "timeFrame": "Baseline, 1, 4, 24, and 72 hours after the first dose.",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort 1",
              "description": "enoblituzumab 3 mg/kg IV weekly for up to 51 doses plus pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG001",
              "title": "Cohort 2",
              "description": "enoblituzumab 10 mg/kg IV weekly for up to 51 doses plus pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG002",
              "title": "Cohort 3 and Expansion Cohorts",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses plus pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG003",
              "title": "Cohort 4",
              "description": "enoblituzumab 15 mg/kg IV and retifanlimab 375 mg IV every three weeks for up to 17 doses."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "6"
                },
                {
                  "groupId": "OG001",
                  "value": "3"
                },
                {
                  "groupId": "OG002",
                  "value": "122"
                },
                {
                  "groupId": "OG003",
                  "value": "12"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "223.5",
                      "spread": "62.80"
                    },
                    {
                      "groupId": "OG001",
                      "value": "860.0",
                      "spread": "434.1"
                    },
                    {
                      "groupId": "OG002",
                      "value": "995.4",
                      "spread": "294.4"
                    },
                    {
                      "groupId": "OG003",
                      "value": "580.2",
                      "spread": "133.1"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Mean Trough Concentration of Enoblituzumab",
          "description": "Trough concentration is the concentration measured before the a subsequent dose of enoblituzumab.\n\nMGA271 is characterized by a biphasic concentration-time profile and PPK was used to estimate PK parameters at each dose level",
          "populationDescription": "All participants who received at least one dose of study treatment, date and time of dose administration and relative PK sample collection are known and have sufficient concentration data to derive the PK parameter. PK parameters are analyzed by the dose received. Participants in Cohort 3 and the Expansion Cohorts were combined since all participants were dosed at 15 mg/kg.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "mcg/mL",
          "timeFrame": "At baseline, and Day 7.",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort 1",
              "description": "enoblituzumab 3 mg/kg IV weekly for up to 51 doses plus pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG001",
              "title": "Cohort 2",
              "description": "enoblituzumab 10 mg/kg IV weekly for up to 51 doses plus pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG002",
              "title": "Cohort 3 and Expansion Cohorts",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses plus pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG003",
              "title": "Cohort 4",
              "description": "enoblituzumab 15 mg/kg IV and retifanlimab 375 mg IV every three weeks for up to 17 doses."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "6"
                },
                {
                  "groupId": "OG001",
                  "value": "3"
                },
                {
                  "groupId": "OG002",
                  "value": "122"
                },
                {
                  "groupId": "OG003",
                  "value": "12"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "146.2",
                      "spread": "48.1"
                    },
                    {
                      "groupId": "OG001",
                      "value": "551.0",
                      "spread": "323.7"
                    },
                    {
                      "groupId": "OG002",
                      "value": "607.3",
                      "spread": "246.4"
                    },
                    {
                      "groupId": "OG003",
                      "value": "180.2",
                      "spread": "88.0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Mean Area Under the Concentration Time Curve (AUC) From Time 0 to Day 7 of Enoblituzumab",
          "description": "AUC is the total body exposure to enoblituzumab MGA271 is characterized by a biphasic concentration-time profile and PPK was used to estimate PK parameters at each dose level",
          "populationDescription": "All participants who received at least one dose of study treatment, date and time of dose administration and relative PK sample collection are known and have sufficient concentration data to derive the PK parameter. PK parameters are analyzed by the dose received. Participants in Cohort 3 and the Expansion Cohorts were combined since all participants were dosed at 15 mg/kg.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "mcg/mL*day",
          "timeFrame": "At baseline, 1, 4, 24, 72 hours, and Day 7.",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort 1",
              "description": "enoblituzumab 3 mg/kg IV weekly for up to 51 doses plus pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG001",
              "title": "Cohort 2",
              "description": "enoblituzumab 10 mg/kg IV weekly for up to 51 doses plus pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG002",
              "title": "Cohort 3 and Expansion Cohorts",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses plus pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG003",
              "title": "Cohort 4",
              "description": "enoblituzumab 15 mg/kg IV and retifanlimab 375 mg IV every three weeks for up to 17 doses."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "6"
                },
                {
                  "groupId": "OG001",
                  "value": "3"
                },
                {
                  "groupId": "OG002",
                  "value": "122"
                },
                {
                  "groupId": "OG003",
                  "value": "12"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1207",
                      "spread": "363.3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "4540",
                      "spread": "2445"
                    },
                    {
                      "groupId": "OG002",
                      "value": "5175",
                      "spread": "1820"
                    },
                    {
                      "groupId": "OG003",
                      "value": "5919",
                      "spread": "2009"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Mean Clearance of Enoblituzumab",
          "description": "Drug clearance is the amount of drug removed from the bloodstream by the body per unit of time.",
          "populationDescription": "All participants who received at least one dose of study treatment, date and time of dose administration and relative PK sample collection are known and have sufficient concentration data to derive the PK parameter. PK parameters are analyzed by the dose received. Participants in Cohort 3 and the Expansion Cohorts were combined since all participants were dosed at 15 mg/kg.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "liters per day",
          "timeFrame": "At baseline, 1, 4, 24, 72 hours, and Day 7.",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort 1",
              "description": "enoblituzumab 3 mg/kg IV weekly for up to 51 doses plus pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG001",
              "title": "Cohort 2",
              "description": "enoblituzumab 10 mg/kg IV weekly for up to 51 doses plus pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG002",
              "title": "Cohort 3 and Expansion Cohorts",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses plus pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG003",
              "title": "Cohort 4",
              "description": "enoblituzumab 15 mg/kg IV and retifanlimab 375 mg IV every three weeks for up to 17 doses."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "6"
                },
                {
                  "groupId": "OG001",
                  "value": "3"
                },
                {
                  "groupId": "OG002",
                  "value": "122"
                },
                {
                  "groupId": "OG003",
                  "value": "12"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0.155",
                      "spread": "0.032"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0.154",
                      "spread": "0.076"
                    },
                    {
                      "groupId": "OG002",
                      "value": "0.235",
                      "spread": "0.079"
                    },
                    {
                      "groupId": "OG003",
                      "value": "0.210",
                      "spread": "0.108"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Mean Volume of Distribution at Steady State of Enoblituzumab in Combination With Pembrolizumab or Retifanlimab",
          "description": "The volume of distribution is related to how much drug is distributed to body tissues, or remains in the bloodstream",
          "populationDescription": "All participants who received at least one dose of study treatment, date and time of dose administration and relative PK sample collection are known and have sufficient concentration data to derive the PK parameter. PK parameters are analyzed by the dose received. Participants in Cohort 3 and the Expansion Cohorts were combined since all participants were dosed at 15 mg/kg.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "liters",
          "timeFrame": "At baseline, 1, 4, 24, and 72 and Day 7.",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort 1",
              "description": "enoblituzumab 3 mg/kg IV weekly for up to 51 doses plus pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG001",
              "title": "Cohort 2",
              "description": "enoblituzumab 10 mg/kg IV weekly for up to 51 doses plus pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG002",
              "title": "Cohort 3 and Expansion Cohorts",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses plus pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG003",
              "title": "Cohort 4",
              "description": "enoblituzumab 15 mg/kg IV and retifanlimab 375 mg IV every three weeks for up to 17 doses."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "6"
                },
                {
                  "groupId": "OG001",
                  "value": "3"
                },
                {
                  "groupId": "OG002",
                  "value": "122"
                },
                {
                  "groupId": "OG003",
                  "value": "12"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "6.053",
                      "spread": "0.986"
                    },
                    {
                      "groupId": "OG001",
                      "value": "4.340",
                      "spread": "0.466"
                    },
                    {
                      "groupId": "OG002",
                      "value": "5.814",
                      "spread": "1.357"
                    },
                    {
                      "groupId": "OG003",
                      "value": "6.299",
                      "spread": "1.009"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Mean Terminal Half-life of Enoblituzumab in Combination With Pembrolizumab or Retifanlimab",
          "description": "Terminal half-life is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium MGA271 is characterized by a biphasic concentration-time profile and PPK was used to estimate PK parameters at each dose level",
          "populationDescription": "All participants who received at least one dose of study treatment, date and time of dose administration and relative PK sample collection are known and have sufficient concentration data to derive the PK parameter. PK parameters are analyzed by the dose received. Participants in Cohort 3 and the Expansion Cohorts were combined since all participants were dosed at 15 mg/kg.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "days",
          "timeFrame": "At baseline, 1, 4, 24, and 72 and Day 7.",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort 1",
              "description": "enoblituzumab 3 mg/kg IV weekly for up to 51 doses plus pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG001",
              "title": "Cohort 2",
              "description": "enoblituzumab 10 mg/kg IV weekly for up to 51 doses plus pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG002",
              "title": "Cohort 3 and Expansion Cohorts",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses plus pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG003",
              "title": "Cohort 4",
              "description": "enoblituzumab 15 mg/kg IV and retifanlimab 375 mg IV every three weeks for up to 17 doses."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "6"
                },
                {
                  "groupId": "OG001",
                  "value": "3"
                },
                {
                  "groupId": "OG002",
                  "value": "122"
                },
                {
                  "groupId": "OG003",
                  "value": "12"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "29.22",
                      "spread": "4.337"
                    },
                    {
                      "groupId": "OG001",
                      "value": "23.27",
                      "spread": "8.001"
                    },
                    {
                      "groupId": "OG002",
                      "value": "20.05",
                      "spread": "6.975"
                    },
                    {
                      "groupId": "OG003",
                      "value": "26.63",
                      "spread": "11.43"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Number of Participants That Develop Enoblituzumab Anti-drug Antibodies (ADA)",
          "populationDescription": "All participants who received at least one dose of enoblituzumab and have at least one ADA sample sufficient for analysis. ADA samples are analyzed by the dose received. Participants in Cohort 3 and the Expansion Cohorts were combined since all participants were dosed at 15 mg/kg.",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "Every 3 weeks throughout the study, average duration 13 months.",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort 1",
              "description": "enoblituzumab 3 mg/kg IV weekly for up to 51 doses plus pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG001",
              "title": "Cohort 2",
              "description": "enoblituzumab 10 mg/kg IV weekly for up to 51 doses plus pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG002",
              "title": "Cohort 3 and Expansion Cohorts",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses plus pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG003",
              "title": "Cohort 4",
              "description": "enoblituzumab 15 mg/kg IV and retifanlimab 375 mg IV every three weeks for up to 17 doses."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "6"
                },
                {
                  "groupId": "OG001",
                  "value": "3"
                },
                {
                  "groupId": "OG002",
                  "value": "124"
                },
                {
                  "groupId": "OG003",
                  "value": "12"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "title": "Negative at baseline and negative post-baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "3"
                    },
                    {
                      "groupId": "OG001",
                      "value": "3"
                    },
                    {
                      "groupId": "OG002",
                      "value": "99"
                    },
                    {
                      "groupId": "OG003",
                      "value": "10"
                    }
                  ]
                },
                {
                  "title": "Negative at baseline and positive at least once post-baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0"
                    },
                    {
                      "groupId": "OG002",
                      "value": "1"
                    },
                    {
                      "groupId": "OG003",
                      "value": "1"
                    }
                  ]
                },
                {
                  "title": "Negative at baseline and not done post-baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0"
                    },
                    {
                      "groupId": "OG002",
                      "value": "7"
                    },
                    {
                      "groupId": "OG003",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Positive at baseline and negative post-baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0"
                    },
                    {
                      "groupId": "OG002",
                      "value": "7"
                    },
                    {
                      "groupId": "OG003",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Positive at baseline and positive at least once post-baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0"
                    },
                    {
                      "groupId": "OG002",
                      "value": "2"
                    },
                    {
                      "groupId": "OG003",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Positive at baseline and not done post-baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0"
                    },
                    {
                      "groupId": "OG002",
                      "value": "4"
                    },
                    {
                      "groupId": "OG003",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Not done at baseline and not done post-baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0"
                    },
                    {
                      "groupId": "OG002",
                      "value": "2"
                    },
                    {
                      "groupId": "OG003",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Not done at baseline and negative post-baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0"
                    },
                    {
                      "groupId": "OG002",
                      "value": "2"
                    },
                    {
                      "groupId": "OG003",
                      "value": "1"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Number of Participants That Develop Retifanlimab ADA",
          "populationDescription": "All participants who received at least one dose of retifanlimab and have at least one ADA sample sufficient for analysis.",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "Every 3 weeks throughout the study, average duration 13 months.",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort 4",
              "description": "enoblituzumab 15 mg/kg IV and retifanlimab 375 mg IV every three weeks for up to 17 doses."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "11"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "title": "Negative at baseline and negative post-baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "11"
                    }
                  ]
                },
                {
                  "title": "Negative at baseline and positive at least once post-baseline",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Objective Response Rate",
          "description": "The number of participants with a complete response (CR) or partial response (PR) to enoblituzumab in combination with pembrolizumab or retifanlimab RECIST 1.1 criteria.",
          "populationDescription": "Analysis performed using Response Evaluable Population that includes participants with baseline tumor assessment and at least 1 post-baseline tumor assessment.. NSCLC and SCCHN cohorts were subdivided by prior exposure to a PD1 or PDL1 inhibitor for the evaluation of efficacy. .",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "percentage of participants",
          "timeFrame": "Six weeks after the first dose, then every 9 weeks throughout study until discontinuation, average 13 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort 1",
              "description": "enoblituzumab 3 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG001",
              "title": "Cohort 2",
              "description": "enoblituzumab 10 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG002",
              "title": "Cohort 3",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG003",
              "title": "Melanoma Cohort",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG004",
              "title": "Urothelial Cancer Cohort",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG005",
              "title": "NSCLC Cohort: PD1/PDL1 Nave",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG006",
              "title": "NSCLC Cohort: PD1/PDL1 Experienced",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG007",
              "title": "SCCHN Cohort: PD1/PDL1 Nave",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG008",
              "title": "SCCHN Cohort: PD1/PDL1 Experienced",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG009",
              "title": "Cohort 4",
              "description": "enoblituzumab 15 mg/kg IV and retifanlimab 375 mg IV every three weeks up to 17 doses."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "6"
                },
                {
                  "groupId": "OG001",
                  "value": "3"
                },
                {
                  "groupId": "OG002",
                  "value": "3"
                },
                {
                  "groupId": "OG003",
                  "value": "15"
                },
                {
                  "groupId": "OG004",
                  "value": "17"
                },
                {
                  "groupId": "OG005",
                  "value": "15"
                },
                {
                  "groupId": "OG006",
                  "value": "19"
                },
                {
                  "groupId": "OG007",
                  "value": "16"
                },
                {
                  "groupId": "OG008",
                  "value": "19"
                },
                {
                  "groupId": "OG009",
                  "value": "12"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0",
                      "lowerLimit": "0",
                      "upperLimit": "45.9"
                    },
                    {
                      "groupId": "OG001",
                      "value": "33.3",
                      "lowerLimit": "0.8",
                      "upperLimit": "90.6"
                    },
                    {
                      "groupId": "OG002",
                      "value": "0",
                      "lowerLimit": "0",
                      "upperLimit": "70.8"
                    },
                    {
                      "groupId": "OG003",
                      "value": "6.7",
                      "lowerLimit": "0.2",
                      "upperLimit": "31.9"
                    },
                    {
                      "groupId": "OG004",
                      "value": "5.9",
                      "lowerLimit": "0.1",
                      "upperLimit": "28.7"
                    },
                    {
                      "groupId": "OG005",
                      "value": "33.3",
                      "lowerLimit": "11.8",
                      "upperLimit": "61.6"
                    },
                    {
                      "groupId": "OG006",
                      "value": "10.5",
                      "lowerLimit": "1.3",
                      "upperLimit": "33.1"
                    },
                    {
                      "groupId": "OG007",
                      "value": "31.3",
                      "lowerLimit": "11.0",
                      "upperLimit": "58.7"
                    },
                    {
                      "groupId": "OG008",
                      "value": "0",
                      "lowerLimit": "0",
                      "upperLimit": "17.6"
                    },
                    {
                      "groupId": "OG009",
                      "value": "16.7",
                      "lowerLimit": "2.1",
                      "upperLimit": "48.4"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "ORR Using Immune-related (ir) RECIST Criteria",
          "description": "The number of participants with a complete response (CR) or partial response (PR) to enoblituzumab in combination with pembrolizumab or retifanlimab using irRECIST 1.1 criteria.",
          "populationDescription": "Analysis performed using Response Evaluable Population that includes participants with baseline tumor assessment and at least 1 post-baseline tumor assessment.. NSCLC and SCCHN cohorts were subdivided by prior exposure to a PD1 or PDL1 inhibitor for the evaluation of efficacy. .",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "percentage of participants",
          "timeFrame": "Six weeks after the first dose, then every 9 weeks throughout study until discontinuation, average 13 months",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort 1",
              "description": "enoblituzumab 3 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG001",
              "title": "Cohort 2",
              "description": "enoblituzumab 10 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG002",
              "title": "Cohort 3",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG003",
              "title": "Melanoma Cohort",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG004",
              "title": "Urothelial Cancer Cohort",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG005",
              "title": "NSCLC Cohort: PD1/PDL1 Nave",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG006",
              "title": "NSCLC Cohort: PD1/PDL1 Experienced",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG007",
              "title": "SCCHN Cohort: PD1/PDL1 Nave",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG008",
              "title": "SCCHN Cohort: PD1/PDL1 Experienced",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG009",
              "title": "Cohort 4",
              "description": "enoblituzumab 15 mg/kg IV and retifanlimab 375 mg IV every three weeks up to 17 doses."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "6"
                },
                {
                  "groupId": "OG001",
                  "value": "3"
                },
                {
                  "groupId": "OG002",
                  "value": "3"
                },
                {
                  "groupId": "OG003",
                  "value": "15"
                },
                {
                  "groupId": "OG004",
                  "value": "17"
                },
                {
                  "groupId": "OG005",
                  "value": "15"
                },
                {
                  "groupId": "OG006",
                  "value": "19"
                },
                {
                  "groupId": "OG007",
                  "value": "16"
                },
                {
                  "groupId": "OG008",
                  "value": "19"
                },
                {
                  "groupId": "OG009",
                  "value": "12"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0",
                      "lowerLimit": "0",
                      "upperLimit": "45.9"
                    },
                    {
                      "groupId": "OG001",
                      "value": "33.3",
                      "lowerLimit": "0.8",
                      "upperLimit": "90.6"
                    },
                    {
                      "groupId": "OG002",
                      "value": "0",
                      "lowerLimit": "0",
                      "upperLimit": "70.8"
                    },
                    {
                      "groupId": "OG003",
                      "value": "6.7",
                      "lowerLimit": "0.2",
                      "upperLimit": "31.9"
                    },
                    {
                      "groupId": "OG004",
                      "value": "5.9",
                      "lowerLimit": "0.1",
                      "upperLimit": "28.7"
                    },
                    {
                      "groupId": "OG005",
                      "value": "33.3",
                      "lowerLimit": "11.8",
                      "upperLimit": "61.6"
                    },
                    {
                      "groupId": "OG006",
                      "value": "5.3",
                      "lowerLimit": "0.1",
                      "upperLimit": "26.0"
                    },
                    {
                      "groupId": "OG007",
                      "value": "31.3",
                      "lowerLimit": "11.0",
                      "upperLimit": "58.7"
                    },
                    {
                      "groupId": "OG008",
                      "value": "0",
                      "lowerLimit": "0",
                      "upperLimit": "17.6"
                    },
                    {
                      "groupId": "OG009",
                      "value": "25.0",
                      "lowerLimit": "5.5",
                      "upperLimit": "57.2"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Best Overall Response (RECIST 1.1)",
          "description": "The participants best response to treatment during their study participation. Responses are categorized as CR, PR, stable disease (SD), progressive disease (PD) or not evaluated (NE)",
          "populationDescription": "Analysis performed using Response Evaluable Population that includes participants with baseline tumor assessment and at least 1 post-baseline tumor assessment.. NSCLC and SCCHN cohorts were subdivided by prior exposure to a PD1 or PDL1 inhibitor for the evaluation of efficacy. .",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "Evaluated at 6 weeks then every 9 weeks throughout the study until discontinuation, average 13 months.",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort 1",
              "description": "enoblituzumab 3 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG001",
              "title": "Cohort 2",
              "description": "enoblituzumab 10 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG002",
              "title": "Cohort 3",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG003",
              "title": "Melanoma Cohort",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG004",
              "title": "Urothelial Cancer Cohort",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG005",
              "title": "NSCLC Cohort: PD1/PDL1 Nave",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG006",
              "title": "NSCLC Cohort: PD1/PDL1 Experienced",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG007",
              "title": "SCCHN Cohort: PD1/PDL1 Nave",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG008",
              "title": "SCCHN Cohort: PD1/PDL1 Experienced",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG009",
              "title": "Cohort 4",
              "description": "enoblituzumab 15 mg/kg IV and retifanlimab 375 mg IV every three weeks up to 17 doses."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "6"
                },
                {
                  "groupId": "OG001",
                  "value": "3"
                },
                {
                  "groupId": "OG002",
                  "value": "3"
                },
                {
                  "groupId": "OG003",
                  "value": "15"
                },
                {
                  "groupId": "OG004",
                  "value": "17"
                },
                {
                  "groupId": "OG005",
                  "value": "15"
                },
                {
                  "groupId": "OG006",
                  "value": "19"
                },
                {
                  "groupId": "OG007",
                  "value": "16"
                },
                {
                  "groupId": "OG008",
                  "value": "19"
                },
                {
                  "groupId": "OG009",
                  "value": "12"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "title": "CR",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0"
                    },
                    {
                      "groupId": "OG002",
                      "value": "0"
                    },
                    {
                      "groupId": "OG003",
                      "value": "0"
                    },
                    {
                      "groupId": "OG004",
                      "value": "0"
                    },
                    {
                      "groupId": "OG005",
                      "value": "0"
                    },
                    {
                      "groupId": "OG006",
                      "value": "0"
                    },
                    {
                      "groupId": "OG007",
                      "value": "1"
                    },
                    {
                      "groupId": "OG008",
                      "value": "0"
                    },
                    {
                      "groupId": "OG009",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "PR",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "1"
                    },
                    {
                      "groupId": "OG002",
                      "value": "0"
                    },
                    {
                      "groupId": "OG003",
                      "value": "1"
                    },
                    {
                      "groupId": "OG004",
                      "value": "1"
                    },
                    {
                      "groupId": "OG005",
                      "value": "5"
                    },
                    {
                      "groupId": "OG006",
                      "value": "2"
                    },
                    {
                      "groupId": "OG007",
                      "value": "4"
                    },
                    {
                      "groupId": "OG008",
                      "value": "0"
                    },
                    {
                      "groupId": "OG009",
                      "value": "2"
                    }
                  ]
                },
                {
                  "title": "SD",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "4"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0"
                    },
                    {
                      "groupId": "OG002",
                      "value": "3"
                    },
                    {
                      "groupId": "OG003",
                      "value": "5"
                    },
                    {
                      "groupId": "OG004",
                      "value": "8"
                    },
                    {
                      "groupId": "OG005",
                      "value": "9"
                    },
                    {
                      "groupId": "OG006",
                      "value": "9"
                    },
                    {
                      "groupId": "OG007",
                      "value": "4"
                    },
                    {
                      "groupId": "OG008",
                      "value": "9"
                    },
                    {
                      "groupId": "OG009",
                      "value": "7"
                    }
                  ]
                },
                {
                  "title": "PD",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    },
                    {
                      "groupId": "OG001",
                      "value": "2"
                    },
                    {
                      "groupId": "OG002",
                      "value": "0"
                    },
                    {
                      "groupId": "OG003",
                      "value": "9"
                    },
                    {
                      "groupId": "OG004",
                      "value": "8"
                    },
                    {
                      "groupId": "OG005",
                      "value": "1"
                    },
                    {
                      "groupId": "OG006",
                      "value": "8"
                    },
                    {
                      "groupId": "OG007",
                      "value": "7"
                    },
                    {
                      "groupId": "OG008",
                      "value": "10"
                    },
                    {
                      "groupId": "OG009",
                      "value": "3"
                    }
                  ]
                },
                {
                  "title": "NE",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0"
                    },
                    {
                      "groupId": "OG002",
                      "value": "0"
                    },
                    {
                      "groupId": "OG003",
                      "value": "0"
                    },
                    {
                      "groupId": "OG004",
                      "value": "0"
                    },
                    {
                      "groupId": "OG005",
                      "value": "0"
                    },
                    {
                      "groupId": "OG006",
                      "value": "0"
                    },
                    {
                      "groupId": "OG007",
                      "value": "0"
                    },
                    {
                      "groupId": "OG008",
                      "value": "0"
                    },
                    {
                      "groupId": "OG009",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Best Overall Response (irRECIST 1.1)",
          "description": "The participants best response to treatment during their study participation. Responses are categorized as CR, PR, stable disease (SD), progressive disease (PD) or not evaluated (NE)",
          "populationDescription": "Analysis performed using Response Evaluable Population that includes participants with baseline tumor assessment and at least 1 post-baseline tumor assessment.. NSCLC and SCCHN cohorts were subdivided by prior exposure to a PD1 or PDL1 inhibitor for the evaluation of efficacy. .",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "Evaluated at 6 weeks then every 9 weeks throughout the study until discontinuation, average 13 months.",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort 1",
              "description": "enoblituzumab 3 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG001",
              "title": "Cohort 2",
              "description": "enoblituzumab 10 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG002",
              "title": "Cohort 3",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG003",
              "title": "Melanoma Cohort",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG004",
              "title": "Urothelial Cancer Cohort",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG005",
              "title": "NSCLC Cohort: PD1/PDL1 Nave",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG006",
              "title": "NSCLC Cohort: PD1/PDL1 Experienced",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG007",
              "title": "SCCHN Cohort: PD1/PDL1 Nave",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG008",
              "title": "SCCHN Cohort: PD1/PDL1 Experienced",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG009",
              "title": "Cohort 4",
              "description": "enoblituzumab 15 mg/kg IV and retifanlimab 375 mg IV every three weeks up to 17 doses."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "6"
                },
                {
                  "groupId": "OG001",
                  "value": "3"
                },
                {
                  "groupId": "OG002",
                  "value": "3"
                },
                {
                  "groupId": "OG003",
                  "value": "15"
                },
                {
                  "groupId": "OG004",
                  "value": "17"
                },
                {
                  "groupId": "OG005",
                  "value": "15"
                },
                {
                  "groupId": "OG006",
                  "value": "19"
                },
                {
                  "groupId": "OG007",
                  "value": "16"
                },
                {
                  "groupId": "OG008",
                  "value": "19"
                },
                {
                  "groupId": "OG009",
                  "value": "12"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "title": "CR",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0"
                    },
                    {
                      "groupId": "OG002",
                      "value": "0"
                    },
                    {
                      "groupId": "OG003",
                      "value": "0"
                    },
                    {
                      "groupId": "OG004",
                      "value": "0"
                    },
                    {
                      "groupId": "OG005",
                      "value": "0"
                    },
                    {
                      "groupId": "OG006",
                      "value": "0"
                    },
                    {
                      "groupId": "OG007",
                      "value": "1"
                    },
                    {
                      "groupId": "OG008",
                      "value": "0"
                    },
                    {
                      "groupId": "OG009",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "PR",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    },
                    {
                      "groupId": "OG001",
                      "value": "1"
                    },
                    {
                      "groupId": "OG002",
                      "value": "0"
                    },
                    {
                      "groupId": "OG003",
                      "value": "1"
                    },
                    {
                      "groupId": "OG004",
                      "value": "1"
                    },
                    {
                      "groupId": "OG005",
                      "value": "5"
                    },
                    {
                      "groupId": "OG006",
                      "value": "1"
                    },
                    {
                      "groupId": "OG007",
                      "value": "4"
                    },
                    {
                      "groupId": "OG008",
                      "value": "0"
                    },
                    {
                      "groupId": "OG009",
                      "value": "3"
                    }
                  ]
                },
                {
                  "title": "SD",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "4"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0"
                    },
                    {
                      "groupId": "OG002",
                      "value": "3"
                    },
                    {
                      "groupId": "OG003",
                      "value": "7"
                    },
                    {
                      "groupId": "OG004",
                      "value": "8"
                    },
                    {
                      "groupId": "OG005",
                      "value": "10"
                    },
                    {
                      "groupId": "OG006",
                      "value": "11"
                    },
                    {
                      "groupId": "OG007",
                      "value": "5"
                    },
                    {
                      "groupId": "OG008",
                      "value": "10"
                    },
                    {
                      "groupId": "OG009",
                      "value": "6"
                    }
                  ]
                },
                {
                  "title": "PD",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    },
                    {
                      "groupId": "OG001",
                      "value": "2"
                    },
                    {
                      "groupId": "OG002",
                      "value": "0"
                    },
                    {
                      "groupId": "OG003",
                      "value": "7"
                    },
                    {
                      "groupId": "OG004",
                      "value": "8"
                    },
                    {
                      "groupId": "OG005",
                      "value": "0"
                    },
                    {
                      "groupId": "OG006",
                      "value": "7"
                    },
                    {
                      "groupId": "OG007",
                      "value": "6"
                    },
                    {
                      "groupId": "OG008",
                      "value": "9"
                    },
                    {
                      "groupId": "OG009",
                      "value": "3"
                    }
                  ]
                },
                {
                  "title": "NE",
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    },
                    {
                      "groupId": "OG001",
                      "value": "0"
                    },
                    {
                      "groupId": "OG002",
                      "value": "0"
                    },
                    {
                      "groupId": "OG003",
                      "value": "0"
                    },
                    {
                      "groupId": "OG004",
                      "value": "0"
                    },
                    {
                      "groupId": "OG005",
                      "value": "0"
                    },
                    {
                      "groupId": "OG006",
                      "value": "0"
                    },
                    {
                      "groupId": "OG007",
                      "value": "0"
                    },
                    {
                      "groupId": "OG008",
                      "value": "0"
                    },
                    {
                      "groupId": "OG009",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Minimum and Maximum Duration of Response (DoR) Per irRECIST 1.1",
          "description": "The duration of response displays the minimum and maximum range in months from the first documented CR or PR until disease progression or death, whichever is first.",
          "populationDescription": "Analysis performed using Response Evaluable Population that includes participants with baseline tumor assessment and at least 1 post-baseline tumor assessment.. NSCLC and SCCHN cohorts were subdivided by prior exposure to a PD1 or PDL1 inhibitor for the evaluation of efficacy. .",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "unitOfMeasure": "months",
          "timeFrame": "Evaluated at 6 weeks then every 9 weeks throughout the study until discontinuation, average13 months.",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort 1",
              "description": "enoblituzumab 3 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG001",
              "title": "Cohort 2",
              "description": "enoblituzumab 10 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG002",
              "title": "Cohort 3",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG003",
              "title": "Melanoma Cohort",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG004",
              "title": "Urothelial Cancer Cohort",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG005",
              "title": "NSCLC Cohort: PD1/PDL1 Nave",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG006",
              "title": "NSCLC Cohort: PD1/PDL1 Experienced",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG007",
              "title": "SCCHN Cohort: PD1/PDL1 Nave",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG008",
              "title": "SCCHN Cohort: PD1/PDL1 Experienced",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG009",
              "title": "Cohort 4",
              "description": "enoblituzumab 15 mg/kg IV and retifanlimab 375 mg IV every three weeks up to 17 doses."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "6"
                },
                {
                  "groupId": "OG001",
                  "value": "3"
                },
                {
                  "groupId": "OG002",
                  "value": "3"
                },
                {
                  "groupId": "OG003",
                  "value": "15"
                },
                {
                  "groupId": "OG004",
                  "value": "17"
                },
                {
                  "groupId": "OG005",
                  "value": "15"
                },
                {
                  "groupId": "OG006",
                  "value": "19"
                },
                {
                  "groupId": "OG007",
                  "value": "16"
                },
                {
                  "groupId": "OG008",
                  "value": "19"
                },
                {
                  "groupId": "OG009",
                  "value": "12"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Minimum DoR",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "NA",
                      "comment": "There were no responses in this group."
                    },
                    {
                      "groupId": "OG001",
                      "value": "25.95"
                    },
                    {
                      "groupId": "OG002",
                      "value": "NA",
                      "comment": "There were no responses in this group."
                    },
                    {
                      "groupId": "OG003",
                      "value": "6.14"
                    },
                    {
                      "groupId": "OG004",
                      "value": "28.89"
                    },
                    {
                      "groupId": "OG005",
                      "value": "3.48"
                    },
                    {
                      "groupId": "OG006",
                      "value": "4.44"
                    },
                    {
                      "groupId": "OG007",
                      "value": "4.17"
                    },
                    {
                      "groupId": "OG008",
                      "value": "NA",
                      "comment": "There were no responses in this group"
                    },
                    {
                      "groupId": "OG009",
                      "value": "3.45"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Maximum DoR",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "NA",
                      "comment": "There were no responses in this group."
                    },
                    {
                      "groupId": "OG001",
                      "value": "25.95"
                    },
                    {
                      "groupId": "OG002",
                      "value": "NA",
                      "comment": "There were no responses in this group."
                    },
                    {
                      "groupId": "OG003",
                      "value": "6.14"
                    },
                    {
                      "groupId": "OG004",
                      "value": "25.89"
                    },
                    {
                      "groupId": "OG005",
                      "value": "32.00"
                    },
                    {
                      "groupId": "OG006",
                      "value": "4.44"
                    },
                    {
                      "groupId": "OG007",
                      "value": "23.72"
                    },
                    {
                      "groupId": "OG008",
                      "value": "NA",
                      "comment": "There were no responses in this group"
                    },
                    {
                      "groupId": "OG009",
                      "value": "6.24"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Minimum and Maximum DoR Per RECIST 1.1",
          "description": "The duration of response displays the minimum and maximum range in months from the first documented CR or PR until disease progression or death, whichever is first.",
          "populationDescription": "Analysis performed using Response Evaluable Population that includes participants with baseline tumor assessment and at least 1 post-baseline tumor assessment.. NSCLC and SCCHN cohorts were subdivided by prior exposure to a PD1 or PDL1 inhibitor for the evaluation of efficacy. .",
          "reportingStatus": "POSTED",
          "paramType": "NUMBER",
          "unitOfMeasure": "months",
          "timeFrame": "Evaluated at 6 weeks then every 9 weeks throughout the study until discontinuation, average 13 months.",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort 1",
              "description": "enoblituzumab 3 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG001",
              "title": "Cohort 2",
              "description": "enoblituzumab 10 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG002",
              "title": "Cohort 3",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG003",
              "title": "Melanoma Cohort",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG004",
              "title": "Urothelial Cancer Cohort",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG005",
              "title": "NSCLC Cohort: PD1/PDL1 Nave",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG006",
              "title": "NSCLC Cohort: PD1/PDL1 Experienced",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG007",
              "title": "SCCHN Cohort: PD1/PDL1 Nave",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG008",
              "title": "SCCHN Cohort: PD1/PDL1 Experienced",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG009",
              "title": "Cohort 4",
              "description": "enoblituzumab 15 mg/kg IV and retifanlimab 375 mg IV every three weeks up to 17 doses."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "6"
                },
                {
                  "groupId": "OG001",
                  "value": "3"
                },
                {
                  "groupId": "OG002",
                  "value": "3"
                },
                {
                  "groupId": "OG003",
                  "value": "15"
                },
                {
                  "groupId": "OG004",
                  "value": "17"
                },
                {
                  "groupId": "OG005",
                  "value": "15"
                },
                {
                  "groupId": "OG006",
                  "value": "19"
                },
                {
                  "groupId": "OG007",
                  "value": "16"
                },
                {
                  "groupId": "OG008",
                  "value": "19"
                },
                {
                  "groupId": "OG009",
                  "value": "12"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Minimum DoR",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "NA",
                      "comment": "There were no responses in this group"
                    },
                    {
                      "groupId": "OG001",
                      "value": "25.95"
                    },
                    {
                      "groupId": "OG002",
                      "value": "NA",
                      "comment": "There were no responses in this group"
                    },
                    {
                      "groupId": "OG003",
                      "value": "6.14"
                    },
                    {
                      "groupId": "OG004",
                      "value": "25.89"
                    },
                    {
                      "groupId": "OG005",
                      "value": "3.48"
                    },
                    {
                      "groupId": "OG006",
                      "value": "4.44"
                    },
                    {
                      "groupId": "OG007",
                      "value": "4.17"
                    },
                    {
                      "groupId": "OG008",
                      "value": "NA",
                      "comment": "There were no responses in this group"
                    },
                    {
                      "groupId": "OG009",
                      "value": "3.45"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Maximum DoR",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "NA",
                      "comment": "There were no responses in this group"
                    },
                    {
                      "groupId": "OG001",
                      "value": "25.95"
                    },
                    {
                      "groupId": "OG002",
                      "value": "NA",
                      "comment": "There were no responses in this group"
                    },
                    {
                      "groupId": "OG003",
                      "value": "6.14"
                    },
                    {
                      "groupId": "OG004",
                      "value": "25.89"
                    },
                    {
                      "groupId": "OG005",
                      "value": "32.00"
                    },
                    {
                      "groupId": "OG006",
                      "value": "4.44"
                    },
                    {
                      "groupId": "OG007",
                      "value": "23.72"
                    },
                    {
                      "groupId": "OG008",
                      "value": "NA",
                      "comment": "There were no responses in this group"
                    },
                    {
                      "groupId": "OG009",
                      "value": "6.24"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Median Progression-free Survival (PFS) Using RECIST 1.1",
          "description": "The time from the first infusion of pembrolizumab or retifanlimab until documented disease progression or death from any cause.",
          "populationDescription": "PFS was calculated using the safety population. NSCLC and SCCHN cohorts were subdivided by prior exposure to a PD1 or PDL1 inhibitor for the evaluation of efficacy only. Safety assessment was conducted regardless of prior exposure to a PD1 or PDL1 inhibitor.",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "months",
          "timeFrame": "Evaluated at 6 weeks then every 9 weeks throughout the study until discontinuation, average 13 months.",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort 1",
              "description": "enoblituzumab 3 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG001",
              "title": "Cohort 2",
              "description": "enoblituzumab 10 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG002",
              "title": "Cohort 3",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG003",
              "title": "Melanoma Cohort",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG004",
              "title": "Urothelial Cancer Cohort",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG005",
              "title": "NSCLC Cohort: PD1/PDL1 Nave",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG006",
              "title": "NSCLC Cohort: PD1/PDL1 Experienced",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG007",
              "title": "SCCHN Cohort: PD1/PDL1 Nave",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG008",
              "title": "SCCHN Cohort: PD1/PDL1 Experienced",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG009",
              "title": "Cohort 4",
              "description": "enoblituzumab 15 mg/kg IV and retifanlimab 375 mg IV every three weeks up to 17 doses."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "6"
                },
                {
                  "groupId": "OG001",
                  "value": "3"
                },
                {
                  "groupId": "OG002",
                  "value": "3"
                },
                {
                  "groupId": "OG003",
                  "value": "17"
                },
                {
                  "groupId": "OG004",
                  "value": "21"
                },
                {
                  "groupId": "OG005",
                  "value": "17"
                },
                {
                  "groupId": "OG006",
                  "value": "23"
                },
                {
                  "groupId": "OG007",
                  "value": "19"
                },
                {
                  "groupId": "OG008",
                  "value": "24"
                },
                {
                  "groupId": "OG009",
                  "value": "12"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "NA",
                      "lowerLimit": "1.41",
                      "upperLimit": "NA",
                      "comment": "The upper limit of the confidence level was not reached."
                    },
                    {
                      "groupId": "OG001",
                      "value": "1.4",
                      "lowerLimit": "1.22",
                      "upperLimit": "NA",
                      "comment": "The upper limit of the confidence level was not reached."
                    },
                    {
                      "groupId": "OG002",
                      "value": "3.6",
                      "lowerLimit": "3.32",
                      "upperLimit": "3.91"
                    },
                    {
                      "groupId": "OG003",
                      "value": "2.0",
                      "lowerLimit": "1.38",
                      "upperLimit": "4.83"
                    },
                    {
                      "groupId": "OG004",
                      "value": "2.2",
                      "lowerLimit": "1.28",
                      "upperLimit": "5.52"
                    },
                    {
                      "groupId": "OG005",
                      "value": "5.1",
                      "lowerLimit": "3.19",
                      "upperLimit": "NA",
                      "comment": "The upper limit of the confidence level was not reached."
                    },
                    {
                      "groupId": "OG006",
                      "value": "3.5",
                      "lowerLimit": "1.41",
                      "upperLimit": "5.75"
                    },
                    {
                      "groupId": "OG007",
                      "value": "3.5",
                      "lowerLimit": "1.28",
                      "upperLimit": "13.83"
                    },
                    {
                      "groupId": "OG008",
                      "value": "1.4",
                      "lowerLimit": "1.35",
                      "upperLimit": "3.55"
                    },
                    {
                      "groupId": "OG009",
                      "value": "4.8",
                      "lowerLimit": "1.38",
                      "upperLimit": "11.96"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Median PFS Using irRECIST 1.1 Criteria",
          "description": "The time from the first infusion of pembrolizumab or retifanlimab until documented disease progression or death from any cause.",
          "populationDescription": "PFS was calculated using the safety population. NSCLC and SCCHN cohorts were subdivided by prior exposure to a PD1 or PDL1 inhibitor for the evaluation of efficacy only. Safety assessment was conducted regardless of prior exposure to a PD1 or PDL1 inhibitor.",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "months",
          "timeFrame": "Evaluated at 6 weeks then every 9 weeks throughout the study until discontinuation, average 13 months.",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort 1",
              "description": "enoblituzumab 3 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG001",
              "title": "Cohort 2",
              "description": "enoblituzumab 10 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG002",
              "title": "Cohort 3",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG003",
              "title": "Melanoma Cohort",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG004",
              "title": "Urothelial Cancer Cohort",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG005",
              "title": "NSCLC Cohort: PD1/PDL1 Nave",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG006",
              "title": "NSCLC Cohort: PD1/PDL1 Experienced",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG007",
              "title": "SCCHN Cohort: PD1/PDL1 Nave",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG008",
              "title": "SCCHN Cohort: PD1/PDL1 Experienced",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG009",
              "title": "Cohort 4",
              "description": "enoblituzumab 15 mg/kg IV and retifanlimab 375 mg IV every three weeks up to 17 doses."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "6"
                },
                {
                  "groupId": "OG001",
                  "value": "3"
                },
                {
                  "groupId": "OG002",
                  "value": "3"
                },
                {
                  "groupId": "OG003",
                  "value": "17"
                },
                {
                  "groupId": "OG004",
                  "value": "21"
                },
                {
                  "groupId": "OG005",
                  "value": "17"
                },
                {
                  "groupId": "OG006",
                  "value": "23"
                },
                {
                  "groupId": "OG007",
                  "value": "19"
                },
                {
                  "groupId": "OG008",
                  "value": "24"
                },
                {
                  "groupId": "OG009",
                  "value": "12"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "NA",
                      "lowerLimit": "1.41",
                      "upperLimit": "NA",
                      "comment": "The upper limit of the confidence level was not reached."
                    },
                    {
                      "groupId": "OG001",
                      "value": "1.4",
                      "lowerLimit": "1.22",
                      "upperLimit": "NA",
                      "comment": "The upper limit of the confidence level was not reached."
                    },
                    {
                      "groupId": "OG002",
                      "value": "3.6",
                      "lowerLimit": "3.32",
                      "upperLimit": "3.91"
                    },
                    {
                      "groupId": "OG003",
                      "value": "2.0",
                      "lowerLimit": "1.38",
                      "upperLimit": "4.83"
                    },
                    {
                      "groupId": "OG004",
                      "value": "2.2",
                      "lowerLimit": "1.28",
                      "upperLimit": "5.52"
                    },
                    {
                      "groupId": "OG005",
                      "value": "5.1",
                      "lowerLimit": "3.19",
                      "upperLimit": "NA",
                      "comment": "The upper limit of the confidence level was not reached."
                    },
                    {
                      "groupId": "OG006",
                      "value": "3.5",
                      "lowerLimit": "1.45",
                      "upperLimit": "5.75"
                    },
                    {
                      "groupId": "OG007",
                      "value": "3.5",
                      "lowerLimit": "1.28",
                      "upperLimit": "13.83"
                    },
                    {
                      "groupId": "OG008",
                      "value": "1.4",
                      "lowerLimit": "1.35",
                      "upperLimit": "3.55"
                    },
                    {
                      "groupId": "OG009",
                      "value": "4.8",
                      "lowerLimit": "1.38",
                      "upperLimit": "11.96"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Median Overall Survival",
          "description": "The time from the first infusion of pembrolizumab or retifanlimab until death from any cause.",
          "populationDescription": "OS was calculated using the safety population. NSCLC and SCCHN cohorts were subdivided by prior exposure to a PD1 or PDL1 inhibitor for the evaluation of efficacy only. Safety assessment was conducted regardless of prior exposure to a PD1 or PDL1 inhibitor.",
          "reportingStatus": "POSTED",
          "paramType": "MEDIAN",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "months",
          "timeFrame": "Evaluated at 6 weeks then every 9 weeks throughout the study until discontinuation, average 13 months.",
          "groups": [
            {
              "id": "OG000",
              "title": "Cohort 1",
              "description": "enoblituzumab 3 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG001",
              "title": "Cohort 2",
              "description": "enoblituzumab 10 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG002",
              "title": "Cohort 3",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG003",
              "title": "Melanoma Cohort",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG004",
              "title": "Urothelial Cancer Cohort",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG005",
              "title": "NSCLC Cohort: PD1/PDL1 Nave",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG006",
              "title": "NSCLC Cohort: PD1/PDL1 Experienced",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG007",
              "title": "SCCHN Cohort: PD1/PDL1 Nave",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG008",
              "title": "SCCHN Cohort: PD1/PDL1 Experienced",
              "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses"
            },
            {
              "id": "OG009",
              "title": "Cohort 4",
              "description": "enoblituzumab 15 mg/kg IV and retifanlimab 375 mg IV every three weeks up to 17 doses."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "6"
                },
                {
                  "groupId": "OG001",
                  "value": "3"
                },
                {
                  "groupId": "OG002",
                  "value": "3"
                },
                {
                  "groupId": "OG003",
                  "value": "17"
                },
                {
                  "groupId": "OG004",
                  "value": "21"
                },
                {
                  "groupId": "OG005",
                  "value": "17"
                },
                {
                  "groupId": "OG006",
                  "value": "23"
                },
                {
                  "groupId": "OG007",
                  "value": "19"
                },
                {
                  "groupId": "OG008",
                  "value": "24"
                },
                {
                  "groupId": "OG009",
                  "value": "12"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "18.0",
                      "lowerLimit": "7.10",
                      "upperLimit": "NA",
                      "comment": "The upper limit of the confidence interval was not reached."
                    },
                    {
                      "groupId": "OG001",
                      "value": "10.3",
                      "lowerLimit": "7.75",
                      "upperLimit": "NA",
                      "comment": "The upper limit of the confidence interval was not reached."
                    },
                    {
                      "groupId": "OG002",
                      "value": "6.3",
                      "lowerLimit": "5.82",
                      "upperLimit": "6.70"
                    },
                    {
                      "groupId": "OG003",
                      "value": "14.4",
                      "lowerLimit": "9.00",
                      "upperLimit": "NA",
                      "comment": "The upper limit of the confidence interval was not reached."
                    },
                    {
                      "groupId": "OG004",
                      "value": "5.7",
                      "lowerLimit": "3.09",
                      "upperLimit": "11.10"
                    },
                    {
                      "groupId": "OG005",
                      "value": "10.3",
                      "lowerLimit": "6.28",
                      "upperLimit": "18.50"
                    },
                    {
                      "groupId": "OG006",
                      "value": "6.0",
                      "lowerLimit": "2.96",
                      "upperLimit": "10.78"
                    },
                    {
                      "groupId": "OG007",
                      "value": "17.9",
                      "lowerLimit": "5.13",
                      "upperLimit": "NA",
                      "comment": "The upper limit of the confidence interval was not reached."
                    },
                    {
                      "groupId": "OG008",
                      "value": "6.9",
                      "lowerLimit": "4.75",
                      "upperLimit": "9.69"
                    },
                    {
                      "groupId": "OG009",
                      "value": "NA",
                      "lowerLimit": "NA",
                      "upperLimit": "NA",
                      "comment": "There were no death events in this cohort by the end of the study. OS and confidence interval could not be calculated."
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "adverseEventsModule": {
      "frequencyThreshold": "5",
      "timeFrame": "Adverse events were collected from the time of first dose through 28 days after the last dose or until the start of another anti-cancer treatment, average 12 months. All cause mortality was assessed from the time of first dose until death, up to 18 months.",
      "description": "Adverse event are based on physical findings, patient reports, and significant laboratory values.\n\nProgression of neoplasm causing hospitalization or death is an antitumor activity outcome and not an SAE, unless considered drug-related by the investigator.\n\nOn participant was enrolled in the study and never treated so the safety population and all-cause mortality is 145.",
      "eventGroups": [
        {
          "id": "EG000",
          "title": "Cohort 1",
          "description": "enoblituzumab 3 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses.",
          "deathsNumAffected": 4,
          "deathsNumAtRisk": 6,
          "seriousNumAffected": 1,
          "seriousNumAtRisk": 6,
          "otherNumAffected": 6,
          "otherNumAtRisk": 6
        },
        {
          "id": "EG001",
          "title": "Cohort 2",
          "description": "enoblituzumab 10 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses.",
          "deathsNumAffected": 2,
          "deathsNumAtRisk": 3,
          "seriousNumAffected": 1,
          "seriousNumAtRisk": 3,
          "otherNumAffected": 3,
          "otherNumAtRisk": 3
        },
        {
          "id": "EG002",
          "title": "Cohort 3",
          "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses.",
          "deathsNumAffected": 2,
          "deathsNumAtRisk": 3,
          "seriousNumAffected": 2,
          "seriousNumAtRisk": 3,
          "otherNumAffected": 3,
          "otherNumAtRisk": 3
        },
        {
          "id": "EG003",
          "title": "Melanoma Cohort",
          "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses.",
          "deathsNumAffected": 11,
          "deathsNumAtRisk": 17,
          "seriousNumAffected": 8,
          "seriousNumAtRisk": 17,
          "otherNumAffected": 17,
          "otherNumAtRisk": 17
        },
        {
          "id": "EG004",
          "title": "Urothelial Cancer Cohort",
          "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses.",
          "deathsNumAffected": 16,
          "deathsNumAtRisk": 21,
          "seriousNumAffected": 4,
          "seriousNumAtRisk": 21,
          "otherNumAffected": 21,
          "otherNumAtRisk": 21
        },
        {
          "id": "EG005",
          "title": "NSCLC Cohort",
          "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses.",
          "deathsNumAffected": 33,
          "deathsNumAtRisk": 40,
          "seriousNumAffected": 14,
          "seriousNumAtRisk": 40,
          "otherNumAffected": 40,
          "otherNumAtRisk": 40
        },
        {
          "id": "EG006",
          "title": "SCCHN Cohort",
          "description": "enoblituzumab 15 mg/kg IV weekly for up to 51 doses and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses.",
          "deathsNumAffected": 30,
          "deathsNumAtRisk": 43,
          "seriousNumAffected": 18,
          "seriousNumAtRisk": 43,
          "otherNumAffected": 42,
          "otherNumAtRisk": 43
        },
        {
          "id": "EG007",
          "title": "Cohort 4",
          "description": "enoblituzumab 15 mg/kg IV and pembrolizumab 2 mg/kg IV every 3 weeks for up to 17 doses.",
          "deathsNumAffected": 0,
          "deathsNumAtRisk": 12,
          "seriousNumAffected": 3,
          "seriousNumAtRisk": 12,
          "otherNumAffected": 12,
          "otherNumAtRisk": 12
        }
      ],
      "seriousEvents": [
        {
          "term": "Granulomatous lymphadenitis",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 1,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Atrial fibrillation",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 2,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Myocarditis",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Atrioventricular block",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Cardiac arrest",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Myocardial infarction",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Pericardial effusion",
          "organSystem": "Cardiac disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Adrenal insufficiency",
          "organSystem": "Endocrine disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Abdominal pain lower",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Colitis",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Gastritis",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Intestinal ischaemia",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Intestinal perforation",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Intussusception",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Large intestinal obstruction",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Small intestinal obstruction",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Non-cardiac chest pain",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Pain",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Pyrexia",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Cytokine release syndrome",
          "organSystem": "Immune system disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Pneumonia",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Septic shock",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 1,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Staphylococcal bacteraemia",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 2,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Bronchitis",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Empyema",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 1,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Mastoiditis",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Sepsis",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 1,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Sepsis syndrome",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Infusion related reaction",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 2,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 2,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 6,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 1,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Fall",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Subdural haematoma",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Aspartate aminotransferase increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 1,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Alanine aminotransferase increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 1,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Hyperkalaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Hyponatraemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Arthralgia",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Back pain",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Muscular weakness",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Musculoskeletal chest pain",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Pathological fracture",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Tumour haemorrhage",
          "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 1,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Cancer pain",
          "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Tumour pain",
          "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 1,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Cerebral artery thrombosis",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Dizziness",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Syncope",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Urinary retention",
          "organSystem": "Renal and urinary disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Pneumonitis",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 4,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Dyspnoea",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 2,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Dyspnoea exertional",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Haemoptysis",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Pleural effusion",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 0,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Pneumonia aspiration",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        }
      ],
      "otherEvents": [
        {
          "term": "Anaemia",
          "organSystem": "Blood and lymphatic system disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 4,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 3,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 3,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 7,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 3,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Hypothyroidism",
          "organSystem": "Endocrine disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 4,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 6,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 1,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Nausea",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 5,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 4,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 13,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 9,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 4,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Constipation",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 7,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 4,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 8,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Diarrhoea",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 3,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 3,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 9,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 4,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Abdominal pain",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 4,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 4,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 5,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 4,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Vomiting",
          "organSystem": "Gastrointestinal disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 2,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 4,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 5,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 4,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Fatigue",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 2,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 7,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 4,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 15,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 19,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 2,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Pyrexia",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 4,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 4,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 2,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 11,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 2,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Chills",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 3,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 5,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Oedema peripheral",
          "organSystem": "General disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 3,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 2,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 3,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 1,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Urinary tract infection",
          "organSystem": "Infections and infestations",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 6,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 3,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 1,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Infusion related reaction",
          "organSystem": "Injury, poisoning and procedural complications",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 2,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 9,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 10,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 24,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 16,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 6,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Lipase increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 2,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 6,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 2,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 1,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Lymphocyte count decreased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 0,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 7,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 1,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Blood alkaline phosphatase increased",
          "organSystem": "Investigations",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 3,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 1,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Decreased appetite",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 2,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 5,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 11,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 5,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 3,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Hypoalbuminaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 5,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 4,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 0,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 4,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 2,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Hyponatraemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 3,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 2,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 5,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 2,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Dehydration",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 2,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 7,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Hyperglycaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 3,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 3,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 3,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Hypophosphataemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 2,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 4,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 2,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Hypomagnesaemia",
          "organSystem": "Metabolism and nutrition disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 3,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 2,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Arthralgia",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 3,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 3,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 8,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 4,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 8,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Back pain",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 6,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 4,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 1,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Pain in extremity",
          "organSystem": "Musculoskeletal and connective tissue disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 2,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 4,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 3,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 3,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Dizziness",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 3,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 3,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 6,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Headache",
          "organSystem": "Nervous system disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 6,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Insomnia",
          "organSystem": "Psychiatric disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 5,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 3,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Haematuria",
          "organSystem": "Renal and urinary disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 3,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 3,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 2,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 2,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Cough",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 3,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 4,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 8,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 7,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 1,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Dyspnoea",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 2,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 2,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 10,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 5,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 1,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Productive cough",
          "organSystem": "Respiratory, thoracic and mediastinal disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 3,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 5,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Rash maculo-papular",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 1,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 1,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 5,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 1,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 2,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Pruritus",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 4,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 2,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 3,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 1,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Rash",
          "organSystem": "Skin and subcutaneous tissue disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 1,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 2,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 0,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 2,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 3,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 2,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Hypotension",
          "organSystem": "Vascular disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 2,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 2,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 4,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 5,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        },
        {
          "term": "Hypertension",
          "organSystem": "Vascular disorders",
          "sourceVocabulary": "MedDRA 24.0",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 0,
              "numAtRisk": 6
            },
            {
              "groupId": "EG001",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG002",
              "numAffected": 0,
              "numAtRisk": 3
            },
            {
              "groupId": "EG003",
              "numAffected": 2,
              "numAtRisk": 17
            },
            {
              "groupId": "EG004",
              "numAffected": 1,
              "numAtRisk": 21
            },
            {
              "groupId": "EG005",
              "numAffected": 1,
              "numAtRisk": 40
            },
            {
              "groupId": "EG006",
              "numAffected": 5,
              "numAtRisk": 43
            },
            {
              "groupId": "EG007",
              "numAffected": 0,
              "numAtRisk": 12
            }
          ]
        }
      ]
    },
    "moreInfoModule": {
      "certainAgreement": {
        "piSponsorEmployee": false,
        "restrictionType": "LTE60",
        "restrictiveAgreement": true
      },
      "pointOfContact": {
        "title": "Chief Medical Officer",
        "organization": "MacroGenics, Inc.",
        "email": "info@macrogenics.com",
        "phone": "301-251-5172"
      }
    }
  },
  "documentSection": {
    "largeDocumentModule": {
      "largeDocs": [
        {
          "typeAbbrev": "Prot",
          "hasProtocol": true,
          "hasSap": false,
          "hasIcf": false,
          "label": "Study Protocol",
          "date": "2020-08-26",
          "uploadDate": "2022-09-28T18:17",
          "filename": "Prot_000.pdf",
          "size": 6121000
        },
        {
          "typeAbbrev": "SAP",
          "hasProtocol": false,
          "hasSap": true,
          "hasIcf": false,
          "label": "Statistical Analysis Plan",
          "date": "2021-06-07",
          "uploadDate": "2022-09-28T18:16",
          "filename": "SAP_001.pdf",
          "size": 3943878
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-11"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D008545",
          "term": "Melanoma"
        },
        {
          "id": "D006258",
          "term": "Head and Neck Neoplasms"
        },
        {
          "id": "D002289",
          "term": "Carcinoma, Non-Small-Cell Lung"
        },
        {
          "id": "D002295",
          "term": "Carcinoma, Transitional Cell"
        }
      ],
      "ancestors": [
        {
          "id": "D018358",
          "term": "Neuroendocrine Tumors"
        },
        {
          "id": "D017599",
          "term": "Neuroectodermal Tumors"
        },
        {
          "id": "D009373",
          "term": "Neoplasms, Germ Cell and Embryonal"
        },
        {
          "id": "D009370",
          "term": "Neoplasms by Histologic Type"
        },
        {
          "id": "D009369",
          "term": "Neoplasms"
        },
        {
          "id": "D009380",
          "term": "Neoplasms, Nerve Tissue"
        },
        {
          "id": "D018326",
          "term": "Nevi and Melanomas"
        },
        {
          "id": "D012878",
          "term": "Skin Neoplasms"
        },
        {
          "id": "D009371",
          "term": "Neoplasms by Site"
        },
        {
          "id": "D012871",
          "term": "Skin Diseases"
        },
        {
          "id": "D017437",
          "term": "Skin and Connective Tissue Diseases"
        },
        {
          "id": "D002283",
          "term": "Carcinoma, Bronchogenic"
        },
        {
          "id": "D001984",
          "term": "Bronchial Neoplasms"
        },
        {
          "id": "D008175",
          "term": "Lung Neoplasms"
        },
        {
          "id": "D012142",
          "term": "Respiratory Tract Neoplasms"
        },
        {
          "id": "D013899",
          "term": "Thoracic Neoplasms"
        },
        {
          "id": "D008171",
          "term": "Lung Diseases"
        },
        {
          "id": "D012140",
          "term": "Respiratory Tract Diseases"
        },
        {
          "id": "D002277",
          "term": "Carcinoma"
        },
        {
          "id": "D009375",
          "term": "Neoplasms, Glandular and Epithelial"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "C582435",
          "term": "pembrolizumab"
        }
      ]
    }
  },
  "hasResults": true
}